A study to evaluate the effect of tender to swollen joint count ratio on treatment response to a first course of biologic disease-modifying antirheumatic drug therapy in Psoriatic Arthritis patients
Latest Information Update: 06 Jul 2022
At a glance
- Drugs Adalimumab (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Methotrexate (Primary) ; Secukinumab (Primary)
- Indications Polyarthritis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 15 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism